Skip to main content
. Author manuscript; available in PMC: 2023 Jul 4.
Published in final edited form as: Clin Cancer Res. 2023 Jan 4;29(1):30–39. doi: 10.1158/1078-0432.CCR-22-1366

Table 2.

Increased blood flow is correlated with better clinical outcome for patients treated with anti-VEGF therapy.

Agents Disease Imaging parameter Clinical Outcome
Cediranib Recurrent GBM Increased blood flow (MRI) Increased PFS and OS [155]
Cediranib + chemoradiotherapy Newly diagnosed GBM Increased blood flow (MRI) Increased PFS and OS [156]
Bevacizumab alone and then with chemotherapy Advanced NSCLC Increased blood flow
(dCT after bevacizumab single agent)		 Increased ORR [157]
Neoadjuvant bevacizumab alone and then with chemotherapy Chemo-naïve breast cancer Increased oxygenation
(FMISO-PET after bevacizumab single agent)		 Increased ORR [158]
Neoadjuvant bevacizumab alone and then with chemotherapy TNBC Vessel density and pericyte coverage
(IHC in serial biopsies after bevacizumab single agent)		 Path response (Miller-Payne score) [159]

GBM, glioblastoma; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; TNBC, triple negative breast cancer. PFS, progression-free survival; OS, overall survival; ORR, objective response rate.